Equibles does not estimate personal net worth.
Get an email with a short summary when Biomarin Pharmaceutical Inc publishes a filing, an earnings call transcript or a press release.
Get BMRN alertsThe proxy statement of Biomarin Pharmaceutical Inc reports total compensation of $5,713,695 for Cristin Hubbard in fiscal 2025, including a base salary of $662,308. Disclosed compensation is on record for 2 fiscal years. Cristin Hubbard has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Biomarin Pharmaceutical Inc on September 9, 2026. Biomarin Pharmaceutical Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Biomarin Pharmaceutical Inc includes Alexander Hardy (CEO and Board Member), Richard A. Meier (Chairman), Brian Mueller (CFO) and 7 others.
“Yeah, so what we've really been focused on with regard to our metabolic conditions business is a platform, a commercialization platform, I would say, that we've built over the last couple of decades at BioMarin.”
“The second quarter demonstrated the strength and growing diversity of our commercial portfolio. Now turning to slide 12. Gallifold and Pombility in OpFolda are off to a strong start as we move quickly to integrate following the April close.”
“We were encouraged by the commercial execution across our portfolio so far this year, with strong patient demand across enzyme therapies and Voxogo. We look forward to providing a more detailed commercial update on our plans to maximize the potential of both Gallifold and Pombility and OpFolda next quarter.”
“The team delivered strong growth in 2024, led by the continued global expansion of Voxogo, increasing Palinzeek penetration, and demand for enzyme replacement products, and we expect 2025 to build on this momentum.”
Proxy statement
Start not stated–present
Last confirmed April 21, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Chief Commercial Officer — | $662,308 | $5,713,695 |
| 2024 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Chief Commercial Officer — — | $382,846 | $6,928,261 |
